RSC Advances-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2019-12-30 爱科研的小霞霞

这个投稿指南在哪找？我在杂志首页没找到呢。

78 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2021-09-19 122954a6m08暂无昵称

审稿速度:1.0
经验分享：
……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb；
2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投

2021.08.14大修（补实验），小修

2020.09.15 补完实验后再次提交修改后的稿件

2020.09.19 接收

总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。

94 0

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2020-05-09 ms3136433039918945

审稿速度:1.0
经验分享：2020.03.15投稿
2020.04.25大修
2020.05.08 提交修改后的稿件
2020.05.09 接受
祝大家好运。

229 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2021-03-12 站在塔尖

棒棒

116 0

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2020-12-29 1e0cf3e5m18(暂无匿称)

审稿速度:1.0 | 投稿命中率:95.0
经验分享：超级水刊，毕业神器，欢迎欢迎

181 0

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2020-12-02 ms4835088974642650

123

178 0

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2020-05-28 ms20000019

123

156 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2020-07-14 14644ca9m28(暂无昵称)

审稿一个月了还没消息

172 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2020-05-28 ms20000019

审稿速度:6.0 | 投稿命中率:95.0
经验分享：哦哦哦

133 0

[GetPortalCommentsPageByObjectIdResponse(id=582390, encodeId=253158239028, content=这个投稿指南在哪找？我在杂志首页没找到呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0022040609, createdName=爱科研的小霞霞, createdTime=Mon Dec 30 00:00:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053081, encodeId=759510530812b, content=审稿速度:1.0 经验分享： ……被拒了半年多，jcmb第一次投稿，送审后建议补实验拒稿，补完实验后再次投jcmb； 2021.07.18投jcmb被拒，建议我转投rsc，说jcmb转投的接受率为67%，为了能够踩点毕业就进行了转投 2021.08.14大修（补实验），小修 2020.09.15 补完实验后再次提交修改后的稿件 2020.09.19 接收 总的来说，自己和导师觉得这个文章其实不错，导师建议再补点实验后继续投jcmb或Macromolecules，但为了毕业，还是顺从了命运的安排；而且考虑到第一篇科研文章，所以脚踏实地一点。总的来说，感谢jcmb的审稿专家提了很多好的建议，RSC的评审专家更看重文章的意义和应用，所以一审回复还可以，提了一个很好的建议和实验补充，补充完后顺利接收，希望能够给大家带来好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52bb2342957, createdName=122954a6m08暂无昵称, createdTime=Sun Sep 19 19:55:19 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860374, encodeId=02688603e445, content=审稿速度:1.0 经验分享：2020.03.15投稿 2020.04.25大修 2020.05.08 提交修改后的稿件 2020.05.09 接受 祝大家好运。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=375a5413962, createdName=ms3136433039918945, createdTime=Sat May 09 13:34:59 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947652, encodeId=7c8594e65218, content=棒棒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Fri Mar 12 13:17:48 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911837, encodeId=2fa791183eed, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：超级水刊，毕业神器，欢迎欢迎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Tue Dec 29 09:24:15 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904280, encodeId=17dc90428063, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKNJaCQ1YpHE0FeC26ic7lKsicWjQayFXm0RoySIAxtAMBJJibm6ia453ftmPsp4TJBqvEa1kxOjyaFsQ/0, createdBy=b3722206592, createdName=ms4835088974642650, createdTime=Wed Dec 02 12:37:22 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600755, encodeId=17e7600e559e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:18:21 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802779, encodeId=e448802e7917, content=审稿一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=386e5125402, createdName=14644ca9m28(暂无昵称), createdTime=Tue Jul 14 18:22:18 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600757, encodeId=f2a2600e5743, content=审稿速度:6.0 | 投稿命中率:95.0 经验分享：哦哦哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:21:01 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600756, encodeId=6f82600e568b, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Thu May 28 20:20:05 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

2020-05-28 ms20000019

审稿速度:2.0 | 投稿命中率:50.0
经验分享：一下

136 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务